Spironolactone as a potential new treatment to prevent arrhythmias in arrhythmogenic cardiomyopathy cell model

HIGHLIGHTS

  • who: Jean-Baptiste Reisqs and collaborators from the Neuromyogene Institute, Claude Bernard University, Lyon, Villeurbanne, France have published the paper: Spironolactone as a Potential New Treatment to Prevent Arrhythmias in Arrhythmogenic Cardiomyopathy Cell Model, in the Journal: (JOURNAL)
  • what: The authors assess the direct effect of SP and its metabolite canrenoic acid (CA) in cardiomyocytes derived from human-induced pluripotent stem cells (hiPSC-CMs) of a patient bearing a missense mutation (c.394C>T) in the DSC2 gene coding for desmocollin 2 and for the amino acid replacement of arginine by cysteine at position 132 . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?